AccuImage wins 510(k) clearance for upgradeAccuImage has received approval from the Food and Drug Administration for its next-generation 3-D software package. The new release can perform high-speed, two- and three-dimensional image processing,
AccuImage has received approval from the Food and Drug Administration for its next-generation 3-D software package. The new release can perform high-speed, two- and three-dimensional image processing, visualization, and transmission between a hospital network and outside networks via the Internet. It runs on Windows 95/98/NT operating systems.
One of the softwares modules, AccuVRT, renders 3-D displays of body structures, and in addition to presurgical planning and postsurgical follow-up, can be used to visualize vascular anomalies, renal disease, and tumor characteristics. Another module, AccuProjector, allows users to perform maximum intensity projection and multiplanar reformatting of medical data, according to the South San Francisco, CA-based firm.
AccuImages software suite can use data from any medical acquisition device vendor. The company has an OEM alliance with Imatron, also of South San Francisco, to provide visualization software for Imatrons ultra-fast CT scanner (PNN 12/98).
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.